Intravitreal injection (IVI) is one of the most performed ophthalmic interventions since the advent of vascular endothelial growth factor (VEGF) inhibitors as standard of care for neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion. This evidence concerns the gene VEGFA and diabetic macular edema.